Effect of anluohuaxian tablet combined with γ-IFN on schistosomal liver fibrosis

Huang, Jiaquan; Huang, Haiyan; Jiao, Yuntao; Ai, Guo; Huang, Tie‐Jun; Lan, Li; Yu, Haijing; Ma, Ke; Xiao, Fei

doi:10.1007/s11596-009-0111-7

Cited by 13 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anluohuaxian is recommended for the treatment of liver fibrosis in China. Anluohuaxian is known to suppress the expression of type I and III collagen mRNAs, the tissue inhibitor of matrix metalloprotease-1 (TIMP-1), and TGF-β1 in patients with liver fibrosis [ 92 ]. Additionally, the pathogeneses of liver fibrosis and lung fibrosis are known to be quite similar [ 93 ].…”

Section: Clinical Trials Of Therapies For Post-covid Lung Fibrosismentioning

confidence: 99%

Lung Fibrosis after COVID-19: Treatment Prospects

et al. 2021

View full text Add to dashboard Cite

At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID). The global medical community has directed its efforts not only to find effective therapies against the deadly pathogen but also to combat the concomitant complications. Two of the most common respiratory manifestations of COVID are a significant reduction in the diffusing capacity of the lungs (DLCO) and the associated pulmonary interstitial damage. One year after moderate COVID, the incidence rate of impaired DLCO and persistent lung damage still exceeds 30%, and one-third of the patients have severe DLCO impairment and fibrotic lung damage. The persistent respiratory complications may cause substantial population morbidity, long-term disability, and even death due to the lung fibrosis progression. The incidence of COVID-induced pulmonary fibrosis caused by COVID can be estimated based on a 15-year observational study of lung pathology after SARS. Most SARS patients with fibrotic lung damage recovered within the first year and then remained healthy; however, in 20% of the cases, significant fibrosis progression was found in 5–10 years. Based on these data, the incidence rate of post-COVID lung fibrosis can be estimated at 2–6% after moderate illness. What is worse, there are reasons to believe that fibrosis may become one of the major long-term complications of COVID, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates. We discuss the use of antifibrotic therapy for idiopathic pulmonary fibrosis, the IN01 vaccine, glucocorticosteroids as well as the stromal vascular fraction for the treatment and rehabilitation of patients with COVID-associated pulmonary damage.

show abstract

Section: Clinical Trials Of Therapies For Post-covid Lung Fibrosismentioning

confidence: 99%

Lung Fibrosis after COVID-19: Treatment Prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…AHP has been proved to be a widely used TCM patent for liver brosis in China [9][10] [11], which was approved by CFDA (license numberZ20010098) and entered the market in 2001. The components of AHP included Radix Rehmanniae, Panax Notoginseng, Hirudo, Calculus Bovis, Lumbricus, Bighead AtractylodesRhizome, Cortex Moutan and Rhubarb etc.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Efficacy and safety of He-He-Shu-Yang Particles plus Anluohuaxian Pills for early liver fibrosis in Chronic Hepatitis B patients: study protocol for a multicenter, randomized controlled trial

Shi

Xiao

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: In recent years, more and more studies revealed that liver fibrosis progression could happen at early stage in chronic hepatitis B (CHB) patients. However, there is no anti-fibrotic agent available at present in modern medicine.He-He-Shu-YangParticles (HHSYP) and Anluohuaxian Pills (AHP)are two commonly used Traditional Chinese Medicine (TCM) agents for liver fibrosis, but there is no data of them for early liver fibrosis(F1 or F2) in multicenter, randomized controlled trial. Therefore, the aim of this study is to evaluate efficacy and safety ofHHSYP plus AHP for early liver fibrosis in CHB patients. Methods/design: For the 72-week randomized controlled study, 480 CHB patients with early liver fibrosis are randomly assigned at a 2:1 ratio to two groups: the intervention group and the placebo group. The intervention group was treated with HHSYP plus AHP. The placebo group was treated with placebo of HHSYP and AHP. The primary end point is the histological change after 72-week treatment.Discussion: Although previous studies have confirmed the anti-fibrosis efficacy of HHSYP and AHP in CHB patients, the efficacy and safety of their combination treatment for early liver fibrosis is still not clear.Therefore, this will be the first multicenter randomized trial to prove the efficacy and safety of combination TCM treatment of HHSYP and AHP for early liver fibrosis, which will use histological changes as the primary end point. This will provide reliable data for the TCM combination treatment of early liver fibrosis and might give a new direction for further international studies on liver fibrosis.Ethics and dissemination: This study protocol was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (BF2018-175-01) and all other participating centers (Project number2018ZX10725506-003).The study findings will be published in peer-reviewed journals and presented at the national and international conferences. Trial registration: Chinese Clinical Trial Registration: ChiCTR1900025897, Registered:13 September 2019, http://www.chictr.org.cn/edit.aspx?pid=40222&htm=4

show abstract

“…The results of related meta-analysis also confirmed that ALHX and Entecavir had a significant effect on liver fibrosis or cirrhosis ( Song et al, 2019 ). An earlier study ( Huang et al, 2009 ) also found that ALHX was also effective in alleviating liver fibrosis caused by schistosomiasis and further confirmed its excellent hepatoprotective and antifibrotic effects.…”

Section: Treatment Of Liver Cirrhosis In Traditional Chinese Medicinementioning

confidence: 64%

Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine

Zheng,

Xue,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Liver cirrhosis arises from liver fibrosis and necroinflammation caused by various mechanisms of hepatic injury. It is a prevalent condition in clinical practice characterized by hepatocellular dysfunction, portal hypertension, and associated complications. Despite its common occurrence, the etiology and pathogenesis of liver cirrhosis remain incompletely understood, posing a significant health threat. Effective prevention of its onset and progression is paramount in medical research. Symptoms often include discomfort in the liver area, while complications such as sarcopenia, hepatic encephalopathy, ascites, upper gastrointestinal bleeding, and infection can arise. While the efficacy of Western medicine in treating liver cirrhosis is uncertain, Chinese medicine offers distinct advantages. This review explores advancements in liver cirrhosis treatment encompassing non-pharmacological and pharmacological modalities. Chinese medicine interventions, including Chinese medicine decoctions, Chinese patent medicines, and acupuncture, exhibit notable efficacy in cirrhosis reversal and offer improved prognoses. Nowadays, the combination of Chinese and Western medicine in the treatment of liver cirrhosis also has considerable advantages, which is worthy of further research and clinical promotion. Standardized treatment protocols based on these findings hold significant clinical implications.

show abstract

Effect of anluohuaxian tablet combined with γ-IFN on schistosomal liver fibrosis

Cited by 13 publications

References 6 publications

Lung Fibrosis after COVID-19: Treatment Prospects

Lung Fibrosis after COVID-19: Treatment Prospects

WITHDRAWN: Efficacy and safety of He-He-Shu-Yang Particles plus Anluohuaxian Pills for early liver fibrosis in Chronic Hepatitis B patients: study protocol for a multicenter, randomized controlled trial

Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine

Contact Info

Product

Resources

About